News

The company, dubbed Qrativ, will leverage on the medical expertise and clinical data of Mayo Clinic’s and on the AI-driven knowledge synthesis platform of nference. Initially, Qrativ will focus

Under the deal, Sanofi will secure $97.5m upfront payment, as well as up to $27.5m based on the achievement of certain regulatory and manufacturing-related milestones. Once the deal

Biognosys' contract research services and tools are successfully applied in biomarker research, drug and target discovery, pathway modeling, mechanisms of action studies and many other areas. Its market

ALV-107 utilises the proprietary Alivio inflammation-targeting technology. The data were presented at the 2017 Drug Discovery and Therapy World Congress in Boston, Massachusetts. "One of the greatest needs

The Kyprolis-based regimen yielded positive results by meeting the key secondary endpoint of overall survival (OS) in what was a second phase 3 trial dubbed as ASPIRE conducted

The company has received approval for Tremfya to treat adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is a

This patent was previously set to expire on April 26, 2020. As part of the agreement, Cialis exclusivity is now expected to end at the earliest on September

The collaboration will leverage the expertise of Queen’s University and Erytech’s ERYCAPS platform technology with the goal of generating in vivo proof-of-concept data in an arginase-1 deficiency animal

The CTL019 is an investigational chimeric antigen receptor T cell (CAR-T) therapy developed to treat patients with r/r B-cell ALL. The recommendation of ODAC was based on the